DexCom (NASDAQ:DXCM) Stock Price Expected to Rise, Citigroup Analyst Says

DexCom (NASDAQ:DXCM) had its price target hoisted by research analysts at Citigroup from $101.00 to $104.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Citigroup’s price target suggests a potential upside of 25.60% from the stock’s current price.

Several other brokerages have also recently weighed in on DXCM. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

DXCM traded down $3.19 on Tuesday, reaching $82.81. The stock had a trading volume of 2,189,228 shares, compared to its average volume of 3,598,312. The firm has a 50-day moving average of $84.82 and a 200-day moving average of $76.85. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a market capitalization of $32.36 billion, a price-to-earnings ratio of 57.96, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts anticipate that DexCom will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter valued at about $25,000. Private Trust Co. NA increased its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of DexCom during the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC raised its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC lifted its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.